A bill requiring the US Food and Drug Administration to describe its consideration of patient experience data in assessing a drug application has a chance of being included in legislation to renew the agency's user fee programs.
Rep. Doris Matsui, D-Calif., withdrew a proposed amendment to include the measure during subcommittee markup of the user fee legislation....






